<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990639</url>
  </required_header>
  <id_info>
    <org_study_id>YWhep091</org_study_id>
    <nct_id>NCT00990639</nct_id>
  </id_info>
  <brief_title>Effect of Candesartan in Alcoholic Liver Fibrosis</brief_title>
  <official_title>Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Alcohol is one of principal causes of hepatic fibrosis. Although the most effective treatment
      for alcoholic hepatic fibrosis is abstinence of alcohol consumption, additive treatment to
      reduce the accumulation of scar tissue can accelerate the improvement of hepatic fibrosis in
      alcoholic liver disease. The renin-angiotensin system can be an attractive antifibrotic
      target in liver. Several lines of evidence indicate that overproduction of angiotensin II(ANG
      II) in chronic liver injury stimulates the activation of hepatic stellate cells(HSCs)
      attributed to fibrogenesis. Additionally, the antifibrotic effect of ANG II blocking agent
      has been shown in various animal models and hepatitis C patients. Hence, drugs that inhibit
      the renin-angiotensin system have promise in ameliorating hepatic fibrosis in chronic liver
      injury. However, no study has been conducted in patients with alcoholic liver disease to
      evaluate the effect ANG II type I receptor blocking agent on hepatic fibrosis.

      Aim:

      This study aimed to investigate the safety and the efficacy of chronic administration of
      candesartan to hepatic fibrosis patients with alcoholic liver disease.

      Methods

      1) Patients with liver fibrosis(F2) were randomized to receive either the angiotensin
      receptor blocker(ARB), candesartan(8 mg/day) with ursodeoxycholic acid(UDCA)(600 mg/day)(n =
      42), or UDCA alone(n = 43) as control for 6 months. 2)All enrolled patients underwent liver
      biopsies twice for measurement of fibrosis score, area of fibrosis and alpha-smooth muscle
      actin(SMA) positive and hydroxyproline. 3) Transforming growth factor-beta1(TGF-beta1),
      collagen-1, angiotensin II type I receptor(AT1-R), tissue inhibitor of
      metalloproteinase-1(TIMP-1), Rac1 and p22phox which represent oxidant stress were also
      measured by real-time RT-PCR before and after 6 months of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of histologic grade of hepatic fibrosis</measure>
    <time_frame>6 month later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimation of safety of candesartan in hepatic fibrosis</measure>
    <time_frame>6 month later</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>candesartan+UDCA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UDCA group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan for hepatic fibrosis</intervention_name>
    <description>Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.
UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months</description>
    <arm_group_label>candesartan+UDCA group</arm_group_label>
    <arm_group_label>UDCA group</arm_group_label>
    <other_name>atacand for hepatic fibrosis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of alcoholic liver disease

          -  METAVIR fibrosis score ≥ 2 in liver biopsy

          -  Alcohol intake has stop during at least 6 months until study enrollment

        Exclusion Criteria:

          -  Hepatocellular carcinoma or other malignancy

          -  Clinically decompensated cirrhosis (Total bilirubin ≥ 5mg/dL or variceal hemorrhage or
             ascites development or hepatic encephalopathy developement)

          -  Chronic liver disease related with other causes except alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Koo Baik, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Wonju College of Medicine Department of Internal Medicine Devision of Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Wonju College of Medicine Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Kangwon-do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, Chung RT. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009 May;29(5):748-53. doi: 10.1111/j.1478-3231.2009.01973.x. Epub 2009 Feb 9.</citation>
    <PMID>19220742</PMID>
  </reference>
  <reference>
    <citation>Rimola A, Londoño MC, Guevara G, Bruguera M, Navasa M, Forns X, García-Retortillo M, García-Valdecasas JC, Rodes J. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation. 2004 Sep 15;78(5):686-91.</citation>
    <PMID>15371669</PMID>
  </reference>
  <reference>
    <citation>Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G, Rizzetto M, Marzano A. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007 Jun;46(6):1026-33. Epub 2007 Feb 9.</citation>
    <PMID>17336417</PMID>
  </reference>
  <reference>
    <citation>Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, Sakuta S. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002 Oct;36(4 Pt 1):1022.</citation>
    <PMID>12297856</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>October 6, 2009</last_update_submitted>
  <last_update_submitted_qc>October 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Soon Koo Baik/ Yonsei University Wonju College of Medicine Department of Internal Medicine Devision of Gastroenterology and Hepatology</name_title>
    <organization>Yonsei University Wonju College of Medicine Department of Internal Medicine Devision of Gastroenterology and Hepatology</organization>
  </responsible_party>
  <keyword>hepatic fibrosis</keyword>
  <keyword>angiotensin II blocking agents</keyword>
  <keyword>alcoholic liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

